Loading organizations...
Encodia develops advanced protein analysis tools centered on single-molecule protein sequencing. Their platform leverages patented ProteoCode technology, employing a novel reverse-translation approach to enable comprehensive and democratized proteomics. This innovative technology aims to bring the analytical rigor and depth of genomic sequencing to the complex study of proteins, providing detailed insights into their structure and function.
The company was co-founded by Dr. Mark S. Chee, a distinguished figure in the life sciences known for his pivotal role as a founder of Illumina, Inc. Dr. Chee, alongside other scientific leaders such as Dr. Nigel Beard, Chief Technology Officer, established Encodia with the core insight that transformative advancements in protein analysis required a paradigm shift akin to the evolution of DNA sequencing.
Encodia primarily serves researchers and organizations seeking deeper understanding of the proteome for applications in drug discovery, diagnostics, and fundamental biological research. The company’s long-term vision is to democratize protein sequencing, thereby making sophisticated proteomic analysis broadly accessible and driving significant advancements across various scientific and medical disciplines.
Encodia has raised $75.0M across 1 funding round.
Encodia has raised $75.0M in total across 1 funding round.
Encodia has raised $75.0M in total across 1 funding round.
Encodia's investors include Northpond Ventures, Andrew ElBardissi, MD, Alexandria Venture Investments, ARCH Venture Partners, Biomatics Capital, Decheng Capital, Google Ventures, Nan Fung Life Sciences, Tao Capital Partners.
Encodia is a San Diego–based biotechnology company developing ProteoCode™, a reverse‑translation platform that converts peptide sequences into DNA libraries so proteins can be read with next‑generation sequencing scale and throughput, enabling large‑scale proteomics and multiomic integration for research and diagnostics purposes[3][1].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick reminder: the above summarizes publicly available company materials and reporting on Encodia’s technology, funding, and positioning[3][2][1].
Encodia has raised $75.0M across 1 funding round. Most recently, it raised $75.0M Series C in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $75.0M Series C | Northpond Ventures, Andrew ElBardissi, MD | Alexandria Venture Investments, ARCH Venture Partners, Biomatics Capital, Decheng Capital, Google Ventures, Nan Fung Life Sciences, Tao Capital Partners |